Ot Broadcast News
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:06:57
- More information
Informações:
Synopsis
Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.
